Results 111 to 120 of about 126,024 (329)

All‐PEG‐Like Block Copolymers Self‐Assemble into Stealth Nanocarriers for Drug Delivery

Advanced Science, EarlyView.
Self‐assembling nanoparticles composed entirely of POEGMA are engineered by exploiting side‐chain–dependent amphiphilicity and tunable thermoresponsive behavior. These single‐material nanocarriers encapsulate diverse hydrophobic drugs with high efficiency, retain therapeutic activity, improve in vivo efficacy, and evade anti‐PEG antibodies.
Parul Sirohi, Brooke E. Silverstein, Yulia Shmidov, Sonal Deshpande, Joy Tong, Yvonne Y. Ma, Chinmay S. Potnis, Soumen Saha, Xinghai Li, Max R. Ney, Sarah Y. Kim, Joshua J. Milligan, Lixin Fan, Matthew L. Becker, Daniel Reker, Ashutosh Chilkoti   +15 more
wiley   +1 more source

Systemic therapies of Hepatocellular carcinoma (HCC): from preclinical to clinical studies [PDF]

, 2014
Introduzione Attualmente i principali punti critici del trattamento dell’HCC avanzato sono: 1) la mancanza di predittori di risposta alla terapia con sorafenib, 2) lo sviluppo resistenze al sorafenib, 3) la mancanza di terapie di seconda linea ...
Marinelli, Sara <1983>
core   +1 more source

Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Advanced Science, EarlyView.
A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji   +17 more
wiley   +1 more source

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

Advanced Science, EarlyView.
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang, Siqi Mu, Juan Zhang, Guisong Shan, Xueqian Li, Ran Wang, Tao Guo, Xiaoyan He   +7 more
wiley   +1 more source

In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

International Journal of Nanomedicine, 2016
Shaomei Yang,1 Bo Zhang,1 Xiaowei Gong,2 Tianqi Wang,1 Yongjun Liu,1 Na Zhang1 1Department of Pharmaceutics, College of Pharmacy, Shandong University, 2Shandong Provincial Key Laboratory of Neuroprotective Drug, Jinan, Shandong Province, People’s ...
Yang S, Zhang B, Gong X, Wang T, Liu Y, Zhang N   +5 more
doaj  

PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma

Cancer Medicine, 2020
Sorafenib has become the only FDA‐approved first‐line therapy for advanced hepatocellular carcinoma (HCC) for more than 10 years, but there is still no validated predictive or prognostic marker.
Pusen Wang, Zhongyi Jiang, Xueni Liu, Kanru Yu, Chunguang Wang, Hao Li, Lin Zhong   +6 more
doaj   +1 more source

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]

, 2018
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V., Khachigian, Levon M., Parish, Christopher R., Sheahan, Anjali V.   +3 more
core   +1 more source

NEAT1–SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines [PDF]

, 2023
Hiroyuki Tsuchiya, Ririko Shinonaga, Hiromi Sakaguchi, Yutaka Kitagawa, Kenji Yoshida   +4 more
openalex   +1 more source

CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response

Advanced Science, EarlyView.
Tumor vascular remodeling is discussed from a chemokine‐centered perspective. This review summarizes the bidirectional, temporal, and tissue‐specific roles of CXC chemokines in regulating vascular function and immune accessibility. A functional vascular normalization score is introduced as a conceptual framework to integrate dynamic vascular and immune
Hongdan Chen, Yinde Huang, Juntong Wu, Ziying Yi, Yao Li, Zeyu Yang, Fan Zhang, Chong Li   +7 more
wiley   +1 more source

The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III

Neoplasia: An International Journal for Oncology Research, 2012
The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC). Although the clinical application of sorafenib has shown good tolerability in the studied populations, it also causes multiple ...
Yaqiong Yang, Hua Jiang, Huiping Gao, Juan Kong, Pengwei Zhang, Suwen Hu, Bizhi Shi, Pengfei Zhang, Ming Yao, Zonghai Li   +9 more
doaj   +1 more source